Entry |
|
Name |
Tyrosine kinase inhibitor to MET exon 14 skipping
|
Definition |
(Capmatinib,Tepotinib) -| MET* |
Expanded |
(D10891,D11073) -| 4233v4 |
Type |
Drug target
|
Gene |
4233 | MET; MET proto-oncogene, receptor tyrosine kinase |
|
Variant |
|
Perturbant |
D10891 | Capmatinib hydrochloride |
D11073 | Tepotinib hydrochloride |
|
Reference |
|
Authors |
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C |
Title |
cMET Exon 14 Skipping: From the Structure to the Clinic. |
Journal |
|
Reference |
|
Authors |
Drilon A, Cappuzzo F, Ou SI, Camidge DR |
Title |
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? |
Journal |
|
LinkDB |
|